An employee of Lupin Limited works at a reception at their headquarters in Mumbai
Drug major Lupin on Wednesday said it has received approval from the US Food and Drug Administration (USFDA) to market a generic version of Tamiflu capsules, used in treating influenza.
The company has received final approval from the US drug regulator to market oseltamivir phosphate capsules, a generic version of Hoffman-La Roche Inc's Tamiflu capsules in strengths of 30 mg, 45 mg, and 75 mg, Lupin said in a statement.
Oseltamivir phosphate capsules are indicated for the treatment of influenza.
As per IMS MAT October 2017 data, the capsules clocked annual sales of around $467.8 million in the US market.
Shares of Lupin closed 0.46 per cent up at Rs 925.05 on the BSE.